Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia

Tefibazumab (Aurexis), a humanized monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A, is under development as adjunctive therapy for serious Staphylococcus aureus infections. Sixty patients with documented S. aureus bacteremia (SAB) were randomized and receiv...

詳細記述

保存先:
書誌詳細
主要な著者: Weems, J. John, Steinberg, James P., Filler, Scott, Baddley, John W., Corey, G. Ralph, Sampathkumar, Priya, Winston, Lisa, John, Joseph F., Kubin, Christine J., Talwani, Rohit, Moore, Thomas, Patti, Joseph M., Hetherington, Seth, Texter, Michele, Wenzel, Eric, Kelley, Violet A., Fowler, Vance G.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Microbiology 2006
主題:
Clinical Therapeutics
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC1538656/
https://ncbi.nlm.nih.gov/pubmed/16870768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00096-06
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料